SUSTAINED RELEASE DELIVERY OF ONE OR MORE AGENTS
First Claim
1. A method to reduce intraocular pressure in an eye of a subject in need thereof, the method comprising:
- administering to the eye an effective amount of an anti-glaucoma agent and an effective amount of a penetration enhancer,wherein at least the anti-glaucoma agent is administered from a lacrimal implant delivery system.
4 Assignments
0 Petitions
Accused Products
Abstract
The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided. Also provided are implants containing a drug core emplacable in a punctum adjacent to an eye of a patient for controlled release of a therapeutic agent such as latanoprost for the treatment of glaucoma, the drug core containing a polymer such as cross-linked silicone, a therapeutic agent, and an excipient, wherein the excipient can increase the rate of release of the agent from the drug core, or can increase the drug loading in the core without loss of desirable homogeneity of the agent within the core, or can improve retention of the agent in the eye or in tear fluid, or can increase corneal penetration of the agent into the eye.
76 Citations
100 Claims
-
1. A method to reduce intraocular pressure in an eye of a subject in need thereof, the method comprising:
-
administering to the eye an effective amount of an anti-glaucoma agent and an effective amount of a penetration enhancer, wherein at least the anti-glaucoma agent is administered from a lacrimal implant delivery system. - View Dependent Claims (2, 3, 4, 5, 7, 8, 9, 12, 14)
-
-
6. (canceled)
-
10-11. -11. (canceled)
-
13. (canceled)
-
15. A method to treat elevated intraocular pressure, the method comprising:
-
inserting a lacrimal implant delivery system through at least one punctum of a subject in need thereof, wherein the lacrimal implant delivery system comprises at least 80 micrograms of latanoprost. - View Dependent Claims (16, 17, 18, 19, 21, 22)
-
-
20. (canceled)
-
23-40. -40. (canceled)
-
41. A lacrimal implant delivery system comprising:
-
an anti-glaucoma agent and a penetration enhancer for disposition into, or configured as, a drug insert or an implant body, wherein the drug insert or the implant body is configured for disposition within or adjacent to a body cavity, duct, tissue or fluid of a subject. - View Dependent Claims (43, 44, 49, 50)
-
-
42. (canceled)
-
45-48. -48. (canceled)
-
51-62. -62. (canceled)
-
63. A method to reduce intraocular pressure in an eye of a subject in need thereof, the method comprising:
-
administering to the eye an effective amount of an anti-glaucoma agent and an effective amount of an artificial tear, wherein at least the anti-glaucoma agent is administered from a lacrimal implant delivery system. - View Dependent Claims (64, 65, 66, 68)
-
-
67. (canceled)
-
69. A drug core comprising:
-
an anti-glaucoma agent and a polymer matrix for disposition into, or configured as, a drug insert or an implant body, the anti-glaucoma agent including at least latanoprost, wherein the drug insert or the implant body includes at least 80 micrograms of latanoprost and is configured for disposition within or adjacent to a body cavity, duct, tissue or fluid of a subject, and wherein an amount of the anti-glaucoma agent in a first volumetric portion of the drug insert or the implant body is similar to an amount of the anti-glaucoma agent in any other second, but equal volumetric portion of the drug insert or the implant body distinct from the first volumetric portion. - View Dependent Claims (70, 71, 74, 76)
-
-
72-73. -73. (canceled)
-
75. (canceled)
-
77-81. -81. (canceled)
-
82. An implant configured for disposition within or adjacent to a body cavity, tissue, duct, or fluid, the implant comprising:
a drug core comprising; (a) a matrix including a polymer; (b) a therapeutic agent dissolved or dispersed within the matrix, and (c) an excipient dissolved or dispersed within the matrix, the excipient configured to any of, (1) modify a release rate of the therapeutic agent into the body cavity, tissue, duct, or fluid relative to a comparable release rate in the absence of an excipient; (2) increase a loading of the therapeutic agent substantially uniformly dissolved or dispersed within the matrix, relative to a comparable loading of the therapeutic agent that is substantially uniformly dissolved or dispersed, in the absence of an excipient; (3) increase retention of the agent at or adjacent to a site of release in a living body or increase penetration of adjacent body tissue by the agent, or both, relative to the retention or penetration or both from a comparable implant in the absence of the excipient; or any combination thereof, wherein an amount of the therapeutic agent in a volumetric portion of the matrix is similar to an amount of the therapeutic agent in any other equal volumetric portion of the matrix; and
, optionally, an implant body adapted to receive the drug core therewithin for placement within the body cavity, tissue, duct, or fluid.- View Dependent Claims (83, 84, 98, 99)
-
85-97. -97. (canceled)
-
100-123. -123. (canceled)
Specification